Skip to content

Lower Limb Surveillance During VA-ECLS

Lower Limb Surveillance During VA-ECLS: Evaluation of Angiography Through the Reperfusion Cannula at VA-ECMO Implantation and of Near Infrared Spectroscopy (NIRS) Monitoring

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03910062
Enrollment
40
Registered
2019-04-10
Start date
2019-04-01
Completion date
2020-06-01
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest, Cardiogenic Shock, Lower Limb Ischemia

Keywords

VA-ECMO, VA-ECLS, Near-Infrared Spectroscopy (NIRS)

Brief summary

Temporary cardiac support by VA-ECLS can lead to lower limb ischemia. The aim of this study is to evaluate a multi-modal strategy (physical examination, NIRS monitoring and angiography through the reperfusion canula) of lower limb surveillance.

Detailed description

VA ECLS is used as a temporary circulatory support during cardiogenic shock and refractory cardiac arrest. Complications of VA ECLS include hemorrhagic, infectious and ischemic events. VA ECLS requires arterial and venous canules which are frequently positioned in the femoral artery and vein, which carries the risk of lower limb ischemia due to retrograde flow and obstruction of the femoral artery lumen. VA ischemia during VA ECLS is frequent (11-52%) and requires the use of reperfusion canula in the femoral common artery on VA ECLS implantation in a primary prevention strategy, before lower limb ischemia occurs. Even with this strategy, lower limb ischemia can occur due to arterial thrombosis, arterial spasm or insufficient blood flow through the reperfusion canula. Lower limb complications are prevented by monitoring of regional oxygen saturation, control of the reperfusion canula position (ultrasound, angiography) and rapid management when lower limb ischemia is suspected. There are no clear recommendations regarding prevention of lower limb complications during VA ECLS and arterial angiography has been described to diagnose ischemic events and evaluate the effectiveness of an intervention such as injection of vasodilators. This study is a prospective evaluation of a strategy to prevent lower limb complications during VA ECLS with a systematic arterial angiography on VA ECLS implantation and when lower limb ischemia is suspected (regional oxygen tissue saturation \<50% or a differential \>15% between both lower limbs) in addition to continuous NIRS monitoring of lower limbs during VA ECLS.

Interventions

PROCEDURELower limb angiography via the reperfusion cannula and NIRS monitoring

Data collection only (lower limb angiography, lower limbs NIRS values).

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Temporary circulatory support with VA ECLS * Age \> 18 years

Exclusion criteria

* Pregnancy * History of iodinated contrast allergy * History of lower limb amputation above the ankle * Lower limb ischemia before starting of VA-ECLS * Femoro-axillary VA-ECLS * Absence of the lower limb reperfusion canula

Design outcomes

Primary

MeasureTime frameDescription
Severe limb ischemia60 daysIschemia leading to surgical intervention, functional sequelae, necrosis of the extremities or compartment syndrome

Secondary

MeasureTime frameDescription
Mortality28 days and 60 daysMortality rate
Incidence of ischemia of the lower limb during ICU stay2 monthsStO2 \< 50% during 4 consecutive minutes AND/OR StO2 differential \> 15% during ICU stay
Incidence of renal replacement therapy during ICU stay2 monthsNumber of patients who underwent renal replacement therapy
Duration of ICU stay60 daysNumber of days in the ICU
Duration of hospital stay60 daysNumber of days in the hospital

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026